货号：E-T202508210001
CAS：N/A
规格：mg
纯度：≥95%
生产商：试剂家

生物活性：Hydroxychloroquine-d5 is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Hydroxychloroquine-d5 相关抗体:
IRF3 Antibody
Toll-Like Receptor 4 Antibody
Toll-Like Receptor 3 Antibody
TLR2 Antibody
Toll-Like Receptor 2 Antibody (YA1932)
TRIF Antibody (YA2263)
TIRAP Antibody (YA2589)
Toll-Like Receptor 9 Antibody (YA3321)
Toll-Like Receptor 7 Antibody (YA2514)
Toll-Like Receptor 5 Antibody (YA3265)
分子量：520.97
Formula：C22H25D5ClN3O9
非标记 CAS：118-42-3
中文名称：羟氯喹-d5；羟基氯喹-d5
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (530 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.
 [Content Brief]
[3]. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar85(3):429-40.
 [Content Brief]
[4]. Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.
 [Content Brief]